In this guide
Active surveillance versus watchful waiting
Active surveillance monitors a diagnosed, generally lower-risk prostate cancer with the intent to offer treatment if findings suggest more significant disease. Watchful waiting often focuses on symptoms and quality of life rather than testing for changes that might trigger curative treatment. They are not interchangeable strategies.
For many men with low-risk disease, active surveillance is a preferred option. Some men with favorable intermediate-risk disease may also be candidates after careful evaluation. A decision cannot be based on Grade Group alone; disease volume, PSA density, biopsy features, age, competing health risks and individual priorities all matter.
What a real surveillance plan contains
Documented dates and a method for addressing an unexpected result. A one-time change commonly warrants confirmation before major decisions.
Scheduled discussion of results, symptoms and any change in overall health or preferences.
An aid to understanding suspicious lesions or changes, not a universal substitute for tissue sampling.
An agreed approach to confirm initial risk and reassess grade over time, personalized to the case and clinician's protocol.
Clarity about what new findings would lead to repeat imaging, tissue sampling, an additional opinion or discussion of treatment.
The exact intervals should come from the treating team. A personalized plan should have dates, a clinician responsible for reviewing results, and an explanation of what would change the recommendation.
What can change the picture
Reasons to revisit surveillance may include confirmed serial PSA increases, concerning changes on MRI, new examination findings or pathology showing higher-grade or greater-volume disease. PSA kinetics alone are imperfect: transient rises happen, and a biopsy finding may carry more weight than a trend.
When a higher Grade Group appears, the amount and kind of new pattern matter. Clinicians may also consider cribriform or intraductal features, PSA density, genomic information when useful, family history and life expectancy. There is no universal rule that one additional data point automatically requires surgery or radiation.
Four misunderstandings to avoid
| Common assumption | What to understand instead |
|---|---|
| “No symptoms means nothing is changing.” | Localized cancer may produce no urinary symptoms. |
| “The MRI looks stable, so no other monitoring is necessary.” | MRI is useful, but it cannot always replace biopsies in a surveillance protocol. |
| “My PSA rose, so the cancer has definitely progressed.” | PSA can fluctuate for noncancer reasons; clinicians assess the full picture. |
| “Surveillance means treatment is off the table.” | It is a deliberate strategy to defer treatment while preserving options if risk changes. |
What to ask before choosing surveillance, and at every follow-up
Questions worth asking
- What features make this cancer suitable for active surveillance?
- What was sampled and could a more significant focus have been missed?
- What are my PSA, MRI and repeat-biopsy schedules?
- What results would prompt us to reassess rather than simply repeat the same plan?
- If the grade or volume changes, what options would we reconsider?
- Who tracks the next test and contacts me if it is missed?
- How does my individual biology or overall health affect this recommendation?
Practical takeaway: Leaving with a written follow-up plan and a way to obtain the complete reports is more useful than leaving with the vague message that the cancer is “slow growing.”
Sources and further reading
These references support the general information above. Decisions about care depend on individual circumstances, and guidance can change.
Continue exploring
This independent educational article explains general information and questions to discuss with healthcare professionals. It is not a diagnosis, treatment plan or substitute for individualized care.